Rhinomed 将来の成長

Future 基準チェック /06

現在、 Rhinomedの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	46.2%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Rhinomed は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

ASX:RNO - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2023	8	-11	-7	-7	N/A
3/31/2023	9	-9	-7	-7	N/A
12/31/2022	9	-7	-7	-6	N/A
9/30/2022	10	-6	-7	-6	N/A
6/30/2022	10	-5	-7	-6	N/A
3/31/2022	8	-6	-6	-5	N/A
12/31/2021	6	-6	-5	-5	N/A
9/30/2021	5	-8	-5	-5	N/A
6/30/2021	4	-9	-5	-5	N/A
3/31/2021	5	-8	-5	-5	N/A
12/31/2020	5	-7	-4	-4	N/A
9/30/2020	5	-7	-5	-5	N/A
6/30/2020	4	-7	-6	-6	N/A
3/31/2020	4	-8	-6	-6	N/A
12/31/2019	4	-8	-6	-6	N/A
9/30/2019	4	-7	-5	-5	N/A
6/30/2019	3	-6	-5	-4	N/A
3/31/2019	3	-5	-4	-4	N/A
12/31/2018	3	-5	-4	-4	N/A
9/30/2018	3	-5	-4	-4	N/A
6/30/2018	2	-4	-4	-4	N/A
3/31/2018	2	-4	-3	-3	N/A
12/31/2017	1	-5	-3	-3	N/A
9/30/2017	2	-5	-3	-3	N/A
6/30/2017	2	-4	-3	-3	N/A
3/31/2017	2	-5	N/A	-4	N/A
12/31/2016	2	-5	N/A	-5	N/A
9/30/2016	1	-5	N/A	-6	N/A
6/30/2016	1	-6	N/A	-6	N/A
3/31/2016	1	-6	N/A	-6	N/A
12/31/2015	1	-6	N/A	-6	N/A
9/30/2015	1	-6	N/A	-5	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-5	N/A	-4	N/A
12/31/2014	0	-5	N/A	-3	N/A
9/30/2014	0	-4	N/A	-3	N/A
6/30/2014	0	-4	N/A	-2	N/A
3/31/2014	0	-4	N/A	-2	N/A
12/31/2013	0	-4	N/A	-2	N/A
9/30/2013	0	-9	N/A	-2	N/A
6/30/2013	0	-15	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RNOの予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: RNOの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: RNOの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: RNOの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: RNOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RNOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Rhinomed 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘